Compounds > ganoderiol f
Page last updated: 2024-12-08

ganoderiol f

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID471008
CHEMBL ID1915761
CHEBI ID172034
SCHEMBL ID902833
MeSH IDM0501561

Synonyms (14)

Synonym
CHEBI:172034
ganoderiol f
26,27-dihydroxylanosta-7,9(11),24-trien-3-one
(5r,10s,13r,14r,17r)-17-[(1r)-6-hydroxy-5-(hydroxymethyl)-1-methyl-hex-4-enyl]-4,4,10,13,14-pentamethyl-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
114567-47-4
bdbm50356920
CHEMBL1915761 ,
SCHEMBL902833
DTXSID00921423
AKOS032948622
(10s,13r,14r,17r)-17-((r)-7-hydroxy-6-(hydroxymethyl)hept-5-en-2-yl)-4,4,10,13,14-pentamethyl-1,5,6,10,12,13,14,15,16,17-decahydro-2h-cyclopenta[a]phenanthren-3(4h)-one
A902268
F92877
lanosta-7,9(11),24-trien-3-one, 26,27-dihydroxy-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseHomo sapiens (human)IC50 (µMol)200.00000.00001.559910.0000AID630340
DNA topoisomerase 1Homo sapiens (human)IC50 (µMol)106.00000.02101.862610.0000AID711429
DNA topoisomerase 2-alphaHomo sapiens (human)IC50 (µMol)17.00000.48004.35649.9400AID711430
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)21.84000.00000.933210.0000AID630339
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tumor necrosis factorHomo sapiens (human)Kd0.01680.00274.29269.7700AID1156798
Retinoic acid receptor RXR-alphaMus musculus (house mouse)EC50 (µMol)5.00000.04001.71805.0000AID629094
Bile acid receptorMus musculus (house mouse)EC50 (µMol)5.00000.15202.04315.0000AID629094
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (221)

Processvia Protein(s)Taxonomy
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
positive regulation of MAP kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of MAPK cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-33 productionTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of miRNA transcriptionTumor necrosis factorHomo sapiens (human)
positive regulation of miRNA transcriptionTumor necrosis factorHomo sapiens (human)
negative regulation of signaling receptor activityTumor necrosis factorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-8 productionTumor necrosis factorHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of synoviocyte proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of I-kappaB phosphorylationTumor necrosis factorHomo sapiens (human)
negative regulation of apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
response to hypoxiaTumor necrosis factorHomo sapiens (human)
microglial cell activationTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine productionTumor necrosis factorHomo sapiens (human)
positive regulation of protein phosphorylationTumor necrosis factorHomo sapiens (human)
negative regulation of endothelial cell proliferationTumor necrosis factorHomo sapiens (human)
negative regulation of L-glutamate import across plasma membraneTumor necrosis factorHomo sapiens (human)
macrophage activation involved in immune responseTumor necrosis factorHomo sapiens (human)
chronic inflammatory response to antigenic stimulusTumor necrosis factorHomo sapiens (human)
leukocyte migration involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
regulation of immunoglobulin productionTumor necrosis factorHomo sapiens (human)
negative regulation of cytokine production involved in immune responseTumor necrosis factorHomo sapiens (human)
positive regulation of chronic inflammatory response to antigenic stimulusTumor necrosis factorHomo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulinTumor necrosis factorHomo sapiens (human)
skeletal muscle contractionTumor necrosis factorHomo sapiens (human)
negative regulation of systemic arterial blood pressureTumor necrosis factorHomo sapiens (human)
glucose metabolic processTumor necrosis factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
inflammatory responseTumor necrosis factorHomo sapiens (human)
humoral immune responseTumor necrosis factorHomo sapiens (human)
JNK cascadeTumor necrosis factorHomo sapiens (human)
circadian rhythmTumor necrosis factorHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsTumor necrosis factorHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageTumor necrosis factorHomo sapiens (human)
response to xenobiotic stimulusTumor necrosis factorHomo sapiens (human)
response to virusTumor necrosis factorHomo sapiens (human)
response to salt stressTumor necrosis factorHomo sapiens (human)
response to fructoseTumor necrosis factorHomo sapiens (human)
negative regulation of heart rateTumor necrosis factorHomo sapiens (human)
vascular endothelial growth factor productionTumor necrosis factorHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of lipid storageTumor necrosis factorHomo sapiens (human)
response to activityTumor necrosis factorHomo sapiens (human)
regulation of metabolic processTumor necrosis factorHomo sapiens (human)
calcium-mediated signalingTumor necrosis factorHomo sapiens (human)
extracellular matrix organizationTumor necrosis factorHomo sapiens (human)
osteoclast differentiationTumor necrosis factorHomo sapiens (human)
sequestering of triglycerideTumor necrosis factorHomo sapiens (human)
cortical actin cytoskeleton organizationTumor necrosis factorHomo sapiens (human)
positive regulation of protein-containing complex assemblyTumor necrosis factorHomo sapiens (human)
positive regulation of fever generationTumor necrosis factorHomo sapiens (human)
negative regulation of myelinationTumor necrosis factorHomo sapiens (human)
response to nutrient levelsTumor necrosis factorHomo sapiens (human)
negative regulation of interleukin-6 productionTumor necrosis factorHomo sapiens (human)
positive regulation of chemokine productionTumor necrosis factorHomo sapiens (human)
positive regulation of fractalkine productionTumor necrosis factorHomo sapiens (human)
positive regulation of type II interferon productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-1 beta productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-18 productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-6 productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-8 productionTumor necrosis factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationTumor necrosis factorHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTumor necrosis factorHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTumor necrosis factorHomo sapiens (human)
toll-like receptor 3 signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityTumor necrosis factorHomo sapiens (human)
response to isolation stressTumor necrosis factorHomo sapiens (human)
response to macrophage colony-stimulating factorTumor necrosis factorHomo sapiens (human)
vasodilationTumor necrosis factorHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTumor necrosis factorHomo sapiens (human)
positive regulation of apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of programmed cell deathTumor necrosis factorHomo sapiens (human)
regulation of canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
negative regulation of protein-containing complex disassemblyTumor necrosis factorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyTumor necrosis factorHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of MAP kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of MAPK cascadeTumor necrosis factorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of JUN kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of neuron apoptotic processTumor necrosis factorHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationTumor necrosis factorHomo sapiens (human)
negative regulation of viral genome replicationTumor necrosis factorHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processTumor necrosis factorHomo sapiens (human)
response to ethanolTumor necrosis factorHomo sapiens (human)
regulation of fat cell differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of fat cell differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of myoblast differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of osteoblast differentiationTumor necrosis factorHomo sapiens (human)
positive regulation of osteoclast differentiationTumor necrosis factorHomo sapiens (human)
positive regulation of protein catabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of action potentialTumor necrosis factorHomo sapiens (human)
positive regulation of cell adhesionTumor necrosis factorHomo sapiens (human)
positive regulation of mitotic nuclear divisionTumor necrosis factorHomo sapiens (human)
negative regulation of DNA-templated transcriptionTumor necrosis factorHomo sapiens (human)
positive regulation of DNA-templated transcriptionTumor necrosis factorHomo sapiens (human)
negative regulation of mitotic cell cycleTumor necrosis factorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of translational initiation by ironTumor necrosis factorHomo sapiens (human)
negative regulation of glucose importTumor necrosis factorHomo sapiens (human)
positive regulation of JNK cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATTumor necrosis factorHomo sapiens (human)
astrocyte activationTumor necrosis factorHomo sapiens (human)
embryonic digestive tract developmentTumor necrosis factorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of inflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of neurogenesisTumor necrosis factorHomo sapiens (human)
regulation of insulin secretionTumor necrosis factorHomo sapiens (human)
positive regulation of synaptic transmissionTumor necrosis factorHomo sapiens (human)
regulation of synapse organizationTumor necrosis factorHomo sapiens (human)
defense response to Gram-positive bacteriumTumor necrosis factorHomo sapiens (human)
cognitionTumor necrosis factorHomo sapiens (human)
leukocyte tethering or rollingTumor necrosis factorHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTumor necrosis factorHomo sapiens (human)
negative regulation of lipid catabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisTumor necrosis factorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of protein transportTumor necrosis factorHomo sapiens (human)
response to glucocorticoidTumor necrosis factorHomo sapiens (human)
positive regulation of hair follicle developmentTumor necrosis factorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTumor necrosis factorHomo sapiens (human)
regulation of synaptic transmission, glutamatergicTumor necrosis factorHomo sapiens (human)
positive regulation of glial cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of vitamin D biosynthetic processTumor necrosis factorHomo sapiens (human)
positive regulation of calcidiol 1-monooxygenase activityTumor necrosis factorHomo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesisTumor necrosis factorHomo sapiens (human)
regulation of branching involved in salivary gland morphogenesisTumor necrosis factorHomo sapiens (human)
negative regulation of vascular wound healingTumor necrosis factorHomo sapiens (human)
negative regulation of branching involved in lung morphogenesisTumor necrosis factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTumor necrosis factorHomo sapiens (human)
cellular response to lipopolysaccharideTumor necrosis factorHomo sapiens (human)
cellular response to amino acid stimulusTumor necrosis factorHomo sapiens (human)
cellular response to retinoic acidTumor necrosis factorHomo sapiens (human)
cellular response to nicotineTumor necrosis factorHomo sapiens (human)
cellular response to type II interferonTumor necrosis factorHomo sapiens (human)
cellular response to ionizing radiationTumor necrosis factorHomo sapiens (human)
positive regulation of mononuclear cell migrationTumor necrosis factorHomo sapiens (human)
positive regulation of podosome assemblyTumor necrosis factorHomo sapiens (human)
endothelial cell apoptotic processTumor necrosis factorHomo sapiens (human)
protein localization to plasma membraneTumor necrosis factorHomo sapiens (human)
negative regulation of oxidative phosphorylationTumor necrosis factorHomo sapiens (human)
inflammatory response to woundingTumor necrosis factorHomo sapiens (human)
extrinsic apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
cellular response to toxic substanceTumor necrosis factorHomo sapiens (human)
liver regenerationTumor necrosis factorHomo sapiens (human)
necroptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of bile acid secretionTumor necrosis factorHomo sapiens (human)
antiviral innate immune responseTumor necrosis factorHomo sapiens (human)
response to Gram-negative bacteriumTumor necrosis factorHomo sapiens (human)
positive regulation of neuroinflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of amyloid-beta clearanceTumor necrosis factorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of amyloid-beta formationTumor necrosis factorHomo sapiens (human)
response to L-glutamateTumor necrosis factorHomo sapiens (human)
positive regulation of neutrophil activationTumor necrosis factorHomo sapiens (human)
positive regulation of protein localization to plasma membraneTumor necrosis factorHomo sapiens (human)
regulation of establishment of endothelial barrierTumor necrosis factorHomo sapiens (human)
negative regulation of bicellular tight junction assemblyTumor necrosis factorHomo sapiens (human)
cellular response to amyloid-betaTumor necrosis factorHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTumor necrosis factorHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellTumor necrosis factorHomo sapiens (human)
regulation of membrane lipid metabolic processTumor necrosis factorHomo sapiens (human)
response to 3,3',5-triiodo-L-thyronineTumor necrosis factorHomo sapiens (human)
response to gold nanoparticleTumor necrosis factorHomo sapiens (human)
positive regulation of protein localization to cell surfaceTumor necrosis factorHomo sapiens (human)
positive regulation of blood microparticle formationTumor necrosis factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionTumor necrosis factorHomo sapiens (human)
positive regulation of hepatocyte proliferationTumor necrosis factorHomo sapiens (human)
regulation of endothelial cell apoptotic processTumor necrosis factorHomo sapiens (human)
regulation of reactive oxygen species metabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of DNA biosynthetic processTumor necrosis factorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandTumor necrosis factorHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
DNA topological changeDNA topoisomerase 1Homo sapiens (human)
chromatin remodelingDNA topoisomerase 1Homo sapiens (human)
circadian rhythmDNA topoisomerase 1Homo sapiens (human)
response to xenobiotic stimulusDNA topoisomerase 1Homo sapiens (human)
programmed cell deathDNA topoisomerase 1Homo sapiens (human)
phosphorylationDNA topoisomerase 1Homo sapiens (human)
peptidyl-serine phosphorylationDNA topoisomerase 1Homo sapiens (human)
circadian regulation of gene expressionDNA topoisomerase 1Homo sapiens (human)
embryonic cleavageDNA topoisomerase 1Homo sapiens (human)
chromosome segregationDNA topoisomerase 1Homo sapiens (human)
DNA replicationDNA topoisomerase 1Homo sapiens (human)
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingTumor necrosis factorHomo sapiens (human)
protease bindingTumor necrosis factorHomo sapiens (human)
cytokine activityTumor necrosis factorHomo sapiens (human)
tumor necrosis factor receptor bindingTumor necrosis factorHomo sapiens (human)
protein bindingTumor necrosis factorHomo sapiens (human)
death receptor agonist activityTumor necrosis factorHomo sapiens (human)
identical protein bindingTumor necrosis factorHomo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 1Homo sapiens (human)
chromatin bindingDNA topoisomerase 1Homo sapiens (human)
double-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
single-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
RNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA topoisomerase type I (single strand cut, ATP-independent) activityDNA topoisomerase 1Homo sapiens (human)
protein serine/threonine kinase activityDNA topoisomerase 1Homo sapiens (human)
protein bindingDNA topoisomerase 1Homo sapiens (human)
ATP bindingDNA topoisomerase 1Homo sapiens (human)
DNA binding, bendingDNA topoisomerase 1Homo sapiens (human)
protein domain specific bindingDNA topoisomerase 1Homo sapiens (human)
supercoiled DNA bindingDNA topoisomerase 1Homo sapiens (human)
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
extracellular spaceTumor necrosis factorHomo sapiens (human)
phagocytic cupTumor necrosis factorHomo sapiens (human)
extracellular regionTumor necrosis factorHomo sapiens (human)
extracellular spaceTumor necrosis factorHomo sapiens (human)
plasma membraneTumor necrosis factorHomo sapiens (human)
external side of plasma membraneTumor necrosis factorHomo sapiens (human)
cell surfaceTumor necrosis factorHomo sapiens (human)
neuronal cell bodyTumor necrosis factorHomo sapiens (human)
membrane raftTumor necrosis factorHomo sapiens (human)
recycling endosomeTumor necrosis factorHomo sapiens (human)
cell surfaceTumor necrosis factorHomo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 1Homo sapiens (human)
P-bodyDNA topoisomerase 1Homo sapiens (human)
fibrillar centerDNA topoisomerase 1Homo sapiens (human)
male germ cell nucleusDNA topoisomerase 1Homo sapiens (human)
nucleusDNA topoisomerase 1Homo sapiens (human)
nucleoplasmDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
perikaryonDNA topoisomerase 1Homo sapiens (human)
protein-DNA complexDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaMus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID779721Ratio of acarbose IC50 to compound IC50 for alpha-glucosidase (unknown origin)2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Structure-activity relationships of lanostane-type triterpenoids from Ganoderma lingzhi as α-glucosidase inhibitors.
AID630339Inhibition of AChE assessed as hydrolysis of acetylcholine preincubated for 15 mins measured after 15 mins by colorimetric Ellman assay2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum.
AID1235930Inhibition of Baker's yeast alpha-glucosidase2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID1235931Inhibition of alpha-glucosidase in rat intestinal mucosa pre-incubated for 40 mins using p-nitrophenyl-alpha-D-glucopyranoside substrate2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID1235935Cytotoxicity against human PC3 cells by MTT method2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID629093Antiinflammatory activity in human HUVEC cells assessed as inhibition of TNF-alpha-induced E-selectin mRNA expression at 5 uM for 10 mins measured after 4 hrs of LPS challenge by Q-PCR analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID736895Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by Griess reaction method2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Inhibitory effect on NO production of triterpenes from the fruiting bodies of Ganoderma lucidum.
AID1235929Inhibition of pig liver microsomes HMG-CoA reductase incubated for 5 mins in using HMG-CoA and NADPH by colorimetric method2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID711421Cytotoxicity against human HuH7 cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID1235933Inhibition of maltase in rat intestinal mucosa pre-incubated for 40 mins using maltose substrate2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID1156798Binding affinity to TNF-alpha (unknown origin)2014European journal of medicinal chemistry, Aug-18, Volume: 83Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID629094Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity after 18 hrs by dual luciferase reporter gene assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID711445Antitumor activity against mouse LLC cells allografted in mouse assessed as reduction in tumor size at 2 mg/kg, ip qd for 2 weeks measured on day 14 relative to control2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID1156800Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID629057Agonist activity at FXR in human HepG2 cells assessed as inhibition of CYP7A1 mRNA expression at 50 uM for 6 hrs by RT-PCR relative to control2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID629058Antiinflammatory activity in human HUVEC cells assessed as inhibition of LPS-induced IL-8 mRNA expression at 5 uM for 10 mins measured after 4 hrs of LPS challenge by Q-PCR analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID1235934Cytotoxicity against human K562 cells by MTT method2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID711424Cytotoxicity against human HepG2 cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711429Inhibition of topoisomerase 12012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID630340Inhibition of BChE assessed as hydrolysis of butrylcholine preincubated for 15 mins measured after 15 mins by colorimetric Ellman assay2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum.
AID711434Antitumor activity against mouse LLC cells allografted in mouse assessed as reduction in tumor size at 5 mg/kg, ip qd for 2 weeks measured on day 14 relative to control2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID736897Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 50 uM after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Inhibitory effect on NO production of triterpenes from the fruiting bodies of Ganoderma lucidum.
AID1156795Retention time of the compound by chromatography2014European journal of medicinal chemistry, Aug-18, Volume: 83Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID711423Cytotoxicity against human K562 cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711433Cytotoxicity against mouse S180 cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711447Antitumor activity against mouse LLC cells allografted in mouse assessed as reduction in tumor size at 10 mg/kg, ip qd for 2 weeks measured on day 20 relative to control2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711446Antitumor activity against mouse LLC cells allografted in mouse assessed as reduction in tumor size at 20 mg/kg, ip qd for 2 weeks measured on day 20 relative to control2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID779722Inhibition of alpha-glucosidase (unknown origin) using sucrose as substrate assessed as formation of glucose after 30 mins by glucose oxidase method2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Structure-activity relationships of lanostane-type triterpenoids from Ganoderma lingzhi as α-glucosidase inhibitors.
AID1235932Inhibition of sucrase in rat intestinal mucosa pre-incubated for 40 mins using sucrose substrate2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID711430Inhibition of topoisomerase 22012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711448Antitumor activity against mouse LLC cells allografted in mouse assessed as reduction in tumor size at 5 mg/kg, ip qd for 2 weeks measured on day 20 relative to control2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711441Cytotoxicity against human HeLa cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID629059Antiinflammatory activity in human HUVEC cells assessed as inhibition of TNF-alpha-induced IL-8 mRNA expression at 5 uM for 10 mins measured after 4 hrs of LPS challenge by Q-PCR analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID711449Antitumor activity against mouse LLC cells allografted in mouse assessed as reduction in tumor size at 20 mg/kg, ip qd for 2 weeks measured on day 14 relative to control2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711428Cytotoxicity against mouse Meth-A cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID629092Antiinflammatory activity in human HUVEC cells assessed as inhibition of LPS-induced E-selectin mRNA expression at 5 uM for 10 mins measured after 4 hrs of LPS challenge by Q-PCR analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID711431Cytotoxicity against mouse LLC cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711422Cytotoxicity against human Hep3B cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711444Antitumor activity against mouse LLC cells allografted in mouse assessed as reduction in tumor size at 2 mg/kg, ip qd for 2 weeks measured on day 20 relative to control2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID736896Cytotoxicity against LPS-stimulated mouse RAW264.7 cells assessed as cell viability at 50 uM after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Inhibitory effect on NO production of triterpenes from the fruiting bodies of Ganoderma lucidum.
AID711432Cytotoxicity against human T47D cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711435Antitumor activity against mouse LLC cells allografted in mouse assessed as reduction in tumor size at 10 mg/kg, ip qd for 2 weeks measured on day 14 relative to control2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's7 (70.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.40 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chenodeoxycholic acid
Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.		2.0610bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
Berberine chloride (TN)
[no description available]		2.0610organic molecular entity
rutamarin
rutamarin: RN given refers to parent cpd; structure		2.0610psoralens
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.1110taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		3.1710beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
atorvastatin
[no description available]		2.1110aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
eburicoic acid
eburicoic acid: structure		3.1710
10-hydroxycamptothecin
[no description available]		3.1710pyranoindolizinoquinoline
daidzin
daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).		2.1107-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
dihydrocapsaicin
[no description available]		2.0610capsaicinoid
oleanolic acid 3-acetate
oleanolic acid 3-acetate: from Gardenia jasminoides; RN given for (3beta)-isomer		2.110
lanosterol
[no description available]		2.051014alpha-methyl steroid;
3beta-sterol;
tetracyclic triterpenoid		bacterial metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
ononin
[no description available]		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
monosaccharide derivative		plant metabolite
acarbose
[no description available]		2.520amino cyclitol;
glycoside
ergosterol
[no description available]		2.08103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols		fungal metabolite;
Saccharomyces cerevisiae metabolite
ganoderic acid a
[no description available]		3.8730triterpenoid
Ganodermanontriol
[no description available]		4.2750triterpenoidmetabolite
formononetin
[no description available]		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite
luteolin
[no description available]		2.1103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
7,3'-dihydroxy-4'-methoxyisoflavone
7,3'-dihydroxy-4'-methoxyisoflavone: isolated from Astragali radix; structure in first source. calycosin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at the 3' position and a methoxy group at the 4' position.		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones		antioxidant;
metabolite
luteolin-7-glucoside
luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.110beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite
apigetrin
apigetrin: structure given in first source. apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.110beta-D-glucoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative		antibacterial agent;
metabolite;
non-steroidal anti-inflammatory drug
ergosta-7,22-dien-3-ol, (3beta,5alpha,6alpha,22e)-isomer
5alpha-ergosta-7,22-dien-3beta-ol : A 3beta-sterol consisting of an ergostane skeleton with double bonds at 7- and 22-positions.		2.08103beta-sterolanti-HSV-1 agent;
antifungal agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
metabolite
calycosin-7-o-beta-d-glucopyranoside
calycosin-7-O-beta-D-glucoside: from Radix Astragali. calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
artemetin
[no description available]		2.0610ether;
flavonoids
spd-304
SPD-304: structure in first source		2.110
ergosterol-5,8-peroxide
ergosterol-5,8-peroxide: also inhibits sulfatase; isolated from fungus Cercospora kikuchii; structure given in first source. ergosterol peroxide : An ergostanoid that is ergosta-6,22-dien-3-ol with a peroxy group between positions 5 and 8 (the 3beta,5alpha,8alpha,22E stereoisomer). Isolated from Ganoderma lucidum and Cordyceps sinensis, it exhibits antimycobacterial, trypanocidal and antineoplastic activities.		2.48203beta-sterol;
ergostanoid;
organic peroxide;
phytosterols		antimycobacterial drug;
antineoplastic agent;
metabolite;
trypanocidal drug
poricoic acid g
poricoic acid G: from Poria cocos (Polyporaceae); structure in first source. poricoic acid G : A tricyclic triterpenoid isolated from Poria cocos.		3.1710dicarboxylic acid;
secondary alcohol;
tricyclic triterpenoid		fungal metabolite
polyporenic acid c
[no description available]		3.1710
diosgenin glucoside
diosgenin glucoside: RN given refers to (3beta,25R)-isomer; structure given in first source. diosgenin 3-O-beta-D-glucoside : A sterol 3-beta-D-glucoside having diosgenin as the sterol component.		2.110hexacyclic triterpenoid;
monosaccharide derivative;
spiroketal;
sterol 3-beta-D-glucoside		metabolite
trametenolic acid b
trametenolic acid B: from Trametes lactinea; structure in first source		3.1710triterpenoid
ganodermadiol
ganodermadiol: isolated from Ganoderma lucidum; structure given in first source. ganoderol B : A tetracyclic triterpenoid that is lanosta-7,9(11),24-triene which is substituted by hydroxy groups at positions 3 and 27. It has been isolated from several Ganoderma species.		4.1403beta-sterol;
primary allylic alcohol;
tetracyclic triterpenoid		antiviral agent;
fungal metabolite;
hepatoprotective agent
astragaloside IV
[no description available]		2.110pentacyclic triterpenoid;
triterpenoid saponin		anti-inflammatory agent;
antioxidant;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
neuroprotective agent;
plant metabolite;
pro-angiogenic agent
lucidenic acid a
lucidenic acid A: isolated from fruiting bodies of Ganoderma lucidum; structure in first source		3.5720triterpenoid
lucidenic acid n
lucidenic acid N: from the dried fruiting bodies of Ganoderma lucidum (polyporaceae); structure in first source. lucidenic acid N : A tetracyclic triterpenoid that is 25,26,27-trinorlanost-8-en-24-oic acid substituted by hydroxy groups at positions 3 and 7 and oxo groups at positions 11 and 15 respectively (the 3beta,5alpha,7beta stereoisomer). Isolated from the fruiting bodies of Ganoderma lucidum, it exhibits cytotoxicity against tumour cells.		2.0610cyclic terpene ketone;
dioxo monocarboxylic acid;
secondary alcohol;
tetracyclic triterpenoid		antineoplastic agent;
EC 3.1.1.8 (cholinesterase) inhibitor;
metabolite
ganoderic acid t
ganoderic acid T: down-regulates expression of both MMP-2 and MMP-9; isolated from Ganoderma lucidum; structure in first source		3.1710
ganoderic acid f
ganoderic acid F: isolated from Ganoderma lucidum; structure in first source		3.5920triterpenoid
inotodiol
inotodiol: structure in first source		3.1710
3,7-dioxolanosta-8,24-dien-26-oic acid
[no description available]		3.5920
ganoderic acid c2
ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source		3.8730triterpenoid
ganoderic acid y
ganoderic acid Y: has antiviral activity; isolated from Ganoderma lucidum; structure in first source		3.8730triterpenoid
7-oxo-ganoderic acid z
7-oxo-ganoderic acid Z: from the mushroom Ganoderma lucidum; structure in first source		3.5920
ganoderic acid a
ganoderic acid A: isolated from Ganoderma lucidum; structure in first source		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatocellular Carcinoma
[description not available]		02.0310
Cancer of Liver
[description not available]		02.0310
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.0310
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0310